title: The feasibility and clinical effects of dendritic cell-based immunotherapy targeting synthesized peptides for recurrent ovarian cancer.
abstract: BACKGROUND
  Despite the increased rate of complete response to initial chemotherapy, most patients with advanced ovarian cancer relapse and succumb to progressive disease. Dendritic cell (DC)-based immunotherapy has been developed as a novel strategy for generating antitumor immunity as part of cancer treatments. The present study aimed to assess the feasibility and clinical effects of DC therapy for recurrent ovarian cancer (ROC).
  
  
  METHODS
  This retrospective study included 56 ROC patients who initially received standard chemotherapy followed by DC-based immunotherapy targeting synthesized peptides at 2 institutions between March 2007 and August 2013. The adverse events (AEs) and clinical responses were examined.
  
  
  RESULTS
  No serious treatment-related AEs were observed. Seventy one percent of the enrolled patients developed an immunologic response. The median survival time (MST) from ROC diagnosis was 30.4 months, and that from the first vaccination was 14.5 months. Albumin levels of ≥4.0 g/dL and lactate dehydrogenase levels of <200 IU/L before vaccination were identified as significant independent factors by multivariate Cox proportional hazard analysis. The MST from the first vaccination in patients with albumin levels of ≥4.0 and <4.0 g/dL were 19.9 and 11.6 months, respectively. The corresponding disease control rates were 36% and 15%, respectively.
  
  
  CONCLUSIONS
  Our results demonstrated the feasibility and potential clinical effectiveness of DC-based immunotherapy for ROC patients. Additionally, a good nutritional status might be an important factor for further clinical effects.
authors.forename: Masanori
authors.initials: M
authors.lastname: Kobayashi
authors.forename: Asako
authors.initials: A
authors.lastname: Chiba
authors.forename: Hiromi
authors.initials: H
authors.lastname: Izawa
authors.forename: Eri
authors.initials: E
authors.lastname: Yanagida
authors.forename: Masato
authors.initials: M
authors.lastname: Okamoto
authors.forename: Shigetaka
authors.initials: S
authors.lastname: Shimodaira
authors.forename: Yoshikazu
authors.initials: Y
authors.lastname: Yonemitsu
authors.forename: Yuta
authors.initials: Y
authors.lastname: Shibamoto
authors.forename: Noboru
authors.initials: N
authors.lastname: Suzuki
authors.forename: Masaki
authors.initials: M
authors.lastname: Nagaya
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D019496:Cancer Vaccines / Q000008:administration & dosage / Q000276:immunology; D003131:Combined Modality Therapy; D003713:Dendritic Cells / Q000276:immunology* / Q000378:metabolism; D005260:Female; D006801:Humans; D007167:Immunotherapy / Q000009:adverse effects; D018655:Lymphocyte Count; D016131:Lymphocyte Subsets / Q000276:immunology; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009364:Neoplasm Recurrence, Local; D010051:Ovarian Neoplasms / Q000175:diagnosis / Q000276:immunology* / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D010455:Peptides / Q000138:chemical synthesis / Q000276:immunology* / Q000378:metabolism; D012189:Retrospective Studies; D037182:T-Cell Antigen Receptor Specificity / Q000276:immunology; D016896:Treatment Outcome; D025721:WT1 Proteins / Q000276:immunology; D055815:Young Adult
chemical_list: D019496:Cancer Vaccines; D010455:Peptides; D025721:WT1 Proteins